Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.770 -0.020 (-0.72%)
Official Closing Price Updated: 4:15 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
News headline image
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio? ↗
The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile. 
Via Benzinga
Topics Artificial Intelligence
News headline image
This Is the Biggest Risk With Iovance Biotherapeutics Stock ↗
Investors should brace for dilution. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest ↗
 
Via Benzinga
News headline image
3 Monster Biotech Stocks to Buy Before 2025 ↗
These companies are nearly in the sweet spot of risk versus reward in biotech. 
Via The Motley Fool
News headline image
Looking Into Iovance Biotherapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
What the Options Market Tells Us About Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? ↗
This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock ↗
It could demonstrate a few capabilities that no other biotech has as of yet. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Iovance Biotherapeutics? ↗
 
Via Benzinga
News headline image
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Shares Are Soaring Today ↗
The biopharma company is proving its recently approved cancer therapy is marketable. 
Via The Motley Fool
News headline image
Why Is Iovance Bio (IOVA) Stock Up 18% Today? ↗
Iovance Biotherapeutics stock is gaining as IOVA investors react to strong Q2 earnings beats and positive guidance for 2024 and 2025. 
Via InvestorPlace
Topics Earnings
News headline image
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges ↗
Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations. 
Via Benzinga
News headline image
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
IOVA Stock Earnings: Iovance Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
IOVA stock results show that Iovance Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
10 Best Small and Mid-Cap Stocks to Consider Buying in August ↗
A shift in market dynamics could favor these 10 growth stocks. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? ↗
Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Stumbled Today ↗
One pundit warns of apparent manufacturing issues with the company's melanoma drug. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy ↗
Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite patient demand, extended treatment timelines and low infusion rates led... 
Via Benzinga
News headline image
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why. ↗
The Federal Reserve's fight against inflation may soon yield financial benefits. 
Via The Motley Fool
Topics Economy
News headline image
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.